UCB’s bimekizumab issued NICE recommendation for severe plaque psoriasis

The National Institute for Health and Care Excellence (NICE) has issued a Final Appraisal Determination (FAD), recommending UCB’s bimekizumab as an option for the treatment of adults with severe plaque psoriasis, a common, chronic immune-mediated systemic disease resulting from sustained inflammation and primarily impacting the skin.